|
1
|
Graudal N, Hubeck-Graudal T, Tarp S,
Christensen R and Jurgens G: Effect of combination therapy on joint
destruction in rheumatoid arthritis: A network meta-analysis of
randomized controlled trials. PLoS One. 9:e1064082014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tang N, Song WX, Luo J, Haydon RC and He
TC: Osteosarcoma development and stem cell differentiation. Clin
Orthop Relat Res. 466:2114–2130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marina N, Gebhardt M, Teot L and Gorlick
R: Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Price CH: Osteogenic sarcoma; an analysis
of the age and sex incidence. Br J Cancer. 9:558–574. 1955.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weinfeld MS and Dudley HR Jr: Osteogenic
sarcoma. A follow-up study of the ninety-four cases observed at the
Massachusetts General Hospital from 1920 to 1960. J Bone Joint Surg
Am. 44-A. pp. 269–276. 1962
|
|
7
|
Dahlin DC and Coventry MB: Osteogenic
sarcoma. A study of six hundred cases. J Bone Joint Surg Am.
49:101–110. 1967.PubMed/NCBI
|
|
8
|
Ando K, Heymann MF, Stresing V, Mori K,
Redini F and Heymann D: Current therapeutic strategies and novel
approaches in osteosarcoma. Cancers (Basel). 5:591–616. 2013.
View Article : Google Scholar
|
|
9
|
Anderson PM and Pearson M: Novel
therapeutic approaches in pediatric and young adult sarcomas. Curr
Oncol Rep. 8:310–315. 2006. View Article : Google Scholar
|
|
10
|
Lin H, Tsai SC, Chen JJ, Chiao YC, Wang
SW, Wang GJ, Chen CF and Wang PS: Effects of evodiamine on the
secretion of testosterone in rat testicular interstitial cells.
Metabolism. 48:1532–1535. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chiou WF, Sung YJ, Liao JF, Shum AY and
Chen CF: Inhibitory effect of dehydroevodiamine and evodiamine on
nitric oxide production in cultured murine macrophages. J Nat Prod.
60:708–711. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kobayashi Y: The nociceptive and
anti-nociceptive effects of evodiamine from fruits of Evodia
rutaecarpa in mice. Planta Med. 69:425–428. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
King CL, Kong YC, Wong NS, Yeung HW, Fong
HH and Sankawa U: Uterotonic effect of Evodia rutaecarpa alkaloids.
J Nat Prod. 43:577–582. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hong JY, Park SH, Min HY, Park HJ and Lee
SK: Anti-proliferative effects of evodiamine in human lung cancer
cells. J Cancer Prev. 19:7–13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Zhang QH, Wu LJ, Tashiro S,
Onodera S and Ikejima T: Atypical apoptosis in L929 cells induced
by evodiamine isolated from Evodia rutaecarpa. J Asian Nat Prod
Res. 6:19–27. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang YC, Guh JH and Teng CM: Induction of
mitotic arrest and apoptosis by evodiamine in human leukemic
T-lymphocytes. Life Sci. 75:35–49. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fei XF, Wang BX, Li TJ, Tashiro S, Minami
M, Xing DJ and Ikejima T: Evodiamine, a constituent of Evodiae
Fructus, induces anti-proliferating effects in tumor cells. Cancer
Sci. 94:92–98. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kan SF, Yu CH, Pu HF, Hsu JM, Chen MJ and
Wang PS: Anti-proliferative effects of evodiamine on human prostate
cancer cell lines DU145 and PC3. J Cell Biochem. 101:44–56. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kan SF, Huang WJ, Lin LC and Wang PS:
Inhibitory effects of evodiamine on the growth of human prostate
cancer cell line LNCaP. Int J Cancer. 110:641–651. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang DM, Guh JH, Huang YT, Chueh SC,
Chiang PC and Teng CM: Induction of mitotic arrest and apoptosis in
human prostate cancer pc-3 cells by evodiamine. J Urol.
173:256–261. 2005. View Article : Google Scholar
|
|
21
|
Yang J, Cai X, Lu W, Hu C, Xu X, Yu Q and
Cao P: Evodiamine inhibits STAT3 signaling by inducing phosphatase
shatterproof 1 in hepatocellular carcinoma cells. Cancer Lett.
328:243–251. 2013. View Article : Google Scholar
|
|
22
|
Porta C, Paglino C and Mosca A: Targeting
PI3K/Akt/mTOR signaling in cancer. Front Oncol. 4:642014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang S and Yu D: PI(3)king apart PTEN's
role in cancer. Clin Cancer Res. 16:4325–4330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mahimainathan L and Choudhury GG:
Inactivation of platelet-derived growth factor receptor by the
tumor suppressor PTEN provides a novel mechanism of action of the
phosphatase. J Biol Chem. 279:15258–15268. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoshimoto M, Cunha IW, Coudry RA, Fonseca
FP, Torres CH, Soares FA and Squire JA: FISH analysis of 107
prostate cancers shows that PTEN genomic deletion is associated
with poor clinical outcome. Br J Cancer. 97:678–685. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ishii N, Maier D, Merlo A, Tada M,
Sawamura Y, Diserens AC and Van Meir EG: Frequent co-alterations of
TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human
glioma cell lines. Brain Pathol. 9:469–479. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Maehama T and Dixon JE: The tumor
suppressor, PTEN/MMAC1, dephosphorylates the lipid second
messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem.
273:13375–13378. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Franke TF, Kaplan DR, Cantley LC and Toker
A: Direct regulation of the Akt proto-oncogene product by
phosphati-dylinositol-3,4-bisphosphate. Science. 275:665–668. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
He BC, Chen L, Zuo GW, Zhang W, Bi Y,
Huang J, Wang Y, Jiang W, Luo Q, Shi Q, et al: Synergistic
antitumor effect of the activated PPARgamma and retinoid receptors
on human osteosarcoma. Clin Cancer Res. 16:2235–2245. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
He TC, Zhou S, da Costa LT, Yu J, Kinzler
KW and Vogelstein B: A simplified system for generating recombinant
adenoviruses. Proc Natl Acad Sci USA. 95:2509–2514. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He BC, Gao JL, Luo X, Luo J, Shen J, Wang
L, Zhou Q, Wang YT, Luu HH, Haydon RC, et al: Ginsenoside Rg3
inhibits colorectal tumor growth through the downregulation of
Wnt/ss-catenin signaling. Int J Oncol. 38:437–445. 2011. View Article : Google Scholar
|
|
32
|
Strzalka W and Ziemienowicz A:
Proliferating cell nuclear antigen (PCNA): A key factor in DNA
replication and cell cycle regulation. Ann Bot. 107:1127–1140.
2011. View Article : Google Scholar :
|
|
33
|
Singha PK, Pandeswara S, Geng H, Lan R,
Venkatachalam MA and Saikumar P: TGF-beta induced TMEPAI/PMEPA1
inhibits canonical Smad signaling through R-Smad sequestration and
promotes non-canonical PI3K/Akt signaling by reducing PTEN in
triple negative breast cancer. Genes Cancer. 5:320–336.
2014.PubMed/NCBI
|
|
34
|
Marques RB, Aghai A, de Ridder CM,
Stuurman D, Hoeben S, Boer A, Ellston RP, Barry ST, Davies BR,
Trapman J, et al: High efficacy of combination therapy using
PI3K/AKT inhibitors with androgen deprivation in prostate cancer
preclinical models. Eur Urol. Sep 11–2014.Epub ahead of print.
PubMed/NCBI
|
|
35
|
Wang J, Chu ES, Chen HY, Man K, Go MY,
Huang XR, Lan HY, Sung JJ and Yu J: microRNA-29b prevents liver
fibrosis by attenuating hepatic stellate cell activation and
inducing apoptosis through targeting PI3K/AKT pathway. Oncotarget.
6:7325–7338. 2014.PubMed/NCBI
|
|
36
|
Yu P, Ye L, Wang H, Du G, Zhang J, Zhang J
and Tian J: NSK-01105 inhibits proliferation and induces apoptosis
of prostate cancer cells by blocking the Raf/MEK/ERK and
PI3K/Akt/mTOR signal pathways. Tumour Biol. 36:2143–2153. 2015.
View Article : Google Scholar
|
|
37
|
Cormier JN and Pollock RE: Soft tissue
sarcomas. CA Cancer J Clin. 54:94–109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gorlick R, Anderson P, Andrulis I, Arndt
C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D,
et al: Biology of childhood osteogenic sarcoma and potential
targets for therapeutic development: meeting summary. Clin Cancer
Res. 9:5442–5453. 2003.PubMed/NCBI
|
|
39
|
Wang L, Hu CP, Deng PY, Shen SS, Zhu HQ,
Ding JS, Tan GS and Li YJ: The protective effects of rutaecarpine
on gastric mucosa injury in rats. Planta Med. 71:416–419. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yu X, Wu DZ, Yuan JY, Zhang RR and Hu ZB:
Gastroprotective effect of fructus evodiae water extract on
ethanol-induced gastric lesions in rats. Am J Chin Med.
34:1027–1035. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liao CH, Pan SL, Guh JH, Chang YL, Pai HC,
Lin CH and Teng CM: Antitumor mechanism of evodiamine, a
constituent from Chinese herb Evodiae fructus, in human
multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro
and in vivo. Carcinogenesis. 26:968–975. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jiang J and Hu C: Evodiamine: a novel
anti-cancer alkaloid from Evodia rutaecarpa. Molecules.
14:1852–1859. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Takada Y, Kobayashi Y and Aggarwal BB:
Evodiamine abolishes constitutive and inducible NF-kappaB
activation by inhibiting IkappaBalpha kinase activation, thereby
suppressing NF-kappaB-regulated antiapoptotic and metastatic gene
expression, upregulating apoptosis, and inhibiting invasion. J Biol
Chem. 280:17203–17212. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chien CC, Wu MS, Shen SC, Ko CH, Chen CH,
Yang LL and Chen YC: Activation of JNK contributes to
evodiamine-induced apoptosis and G2/M arrest in human colorectal
carcinoma cells: a structure-activity study of evodiamine. PLoS
One. 9:e997292014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen MC, Yu CH, Wang SW, Pu HF, Kan SF,
Lin LC, Chi CW, Ho LL, Lee CH and Wang PS: Anti-proliferative
effects of evodiamine on human thyroid cancer cell line ARO. J Cell
Biochem. 110:1495–1503. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lee TJ, Kim EJ, Kim S, Jung EM, Park JW,
Jeong SH, Park SE, Yoo YH and Kwon TK: Caspase-dependent and
caspase-independent apoptosis induced by evodiamine in human
leukemic U937 cells. Mol Cancer Ther. 5:2398–2407. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yu H, Jin H, Gong W, Wang Z and Liang H:
Pharmacological actions of multi-target-directed evodiamine.
Molecules. 18:1826–1843. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu AJ, Wang SH, Chen KC, Kuei HP, Shih
YL, Hou SY, Chiu WT, Hsiao SH and Shih CM: Evodiamine, a plant
alkaloid, induces calcium/JNK-mediated autophagy and
calcium/mitochondria-mediated apoptosis in human glioblastoma
cells. Chem Biol Interact. 205:20–28. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang C, Li S and Wang MW:
Evodiamine-induced human melanoma A375-S2 cell death was mediated
by PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways and
augmented by ubiquitin-proteasome inhibition. Toxicol In Vitro.
24:898–904. 2010. View Article : Google Scholar
|
|
50
|
Ali IU, Schriml LM and Dean M: Mutational
spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid
phosphatase activity. J Natl Cancer Inst. 91:1922–1932. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Freeman SS, Allen SW, Ganti R, Wu J, Ma J,
Su X, Neale G, Dome JS, Daw NC and Khoury JD: Copy number gains in
EGFR and copy number losses in PTEN are common events in
osteosarcoma tumors. Cancer. 113:1453–1461. 2008. View Article : Google Scholar : PubMed/NCBI
|
